MedTrace Logo

Creatine for Depressed Male and Female Methamphetamine Users

NCT02568878 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2015-12-11

No results posted yet for this study

Summary

* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users
* Assess creatine's effect on methamphetamine use
* Assess the safety of creatine in male methamphetamine users with depression

Conditions

Interventions

DRUG

Creatine monohydrate

Sponsors & Collaborators

  • Montana State University

    lead OTHER

Principal Investigators

  • Tracy Hellem, PhD · Montana State University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2016-10-31
Completion
2017-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02568878 on ClinicalTrials.gov